

Masashi Okada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5426843/publications.pdf>

Version: 2024-02-01

49
papers

1,676
citations

257450

24
h-index

302126

39
g-index

49
all docs

49
docs citations

49
times ranked

2670
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. <i>Oncotarget</i> , 2015, 6, 651-661.	1.8	159
2	Glioma-Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK. <i>Stem Cells Translational Medicine</i> , 2012, 1, 811-824.	3.3	155
3	Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8649-8654.	7.1	96
4	Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. <i>Scientific Reports</i> , 2012, 2, 516.	3.3	85
5	JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. <i>Oncotarget</i> , 2015, 6, 458-470.	1.8	83
6	Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. <i>Oncotarget</i> , 2014, 5, 5100-5112.	1.8	56
7	Ebp1 Association with Nucleophosmin/B23 Is Essential for Regulating Cell Proliferation and Suppressing Apoptosis. <i>Journal of Biological Chemistry</i> , 2007, 282, 36744-36754.	3.4	49
8	JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. <i>International Journal of Oncology</i> , 2014, 44, 591-599.	3.3	48
9	The novel JNK inhibitor AS602801 inhibits cancer stem cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 27021-27032.	1.8	48
10	Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells. <i>Oncotarget</i> , 2018, 9, 32667-32679.	1.8	47
11	GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells. <i>Anticancer Research</i> , 2015, 35, 6607-14.	1.1	46
12	JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells. <i>Genes and Cancer</i> , 2013, 4, 388-396.	1.9	44
13	Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells. <i>FEBS Journal</i> , 2020, 287, 2023-2036.	4.7	40
14	Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance. <i>Anticancer Research</i> , 2016, 36, 5153-5162.	1.1	38
15	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells. <i>Oncology Reports</i> , 2013, 30, 1957-1964.	2.6	36
16	Differential contribution of ROS to resveratrol-induced cell death and loss of self-renewal capacity of ovarian cancer stem cells. <i>Anticancer Research</i> , 2015, 35, 85-96.	1.1	32
17	Akt Phosphorylation of Merlin Enhances Its Binding to Phosphatidylinositols and Inhibits the Tumor-Suppressive Activities of Merlin. <i>Cancer Research</i> , 2009, 69, 4043-4051.	0.9	31
18	Interaction of nucleosome assembly proteins abolishes nuclear localization of DCK1 \uparrow by attenuating its association with importins. <i>Experimental Cell Research</i> , 2011, 317, 2853-2863.	2.6	30

#	ARTICLE	IF	CITATIONS
19	Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin. <i>Anticancer Research</i> , 2016, 36, 6083-6092.	1.1	29
20	Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction. <i>FEBS Open Bio</i> , 2017, 7, 835-844.	2.3	28
21	Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug. <i>Oncotarget</i> , 2017, 8, 94872-94882.	1.8	27
22	Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents. <i>Anticancer Research</i> , 2017, 37, 6177-6188.	1.1	27
23	Reciprocal regulation of p53 and NF- κ B by diacylglycerol kinase $\hat{\eta}$. <i>Advances in Biological Regulation</i> , 2016, 60, 15-21.	2.3	26
24	Brexipiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. <i>Cancers</i> , 2019, 11, 947.	3.7	26
25	Downregulation of diacylglycerol kinase $\hat{\eta}$ enhances activation of cytokine-induced NF- κ B signaling pathway. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 361-369.	4.1	24
26	Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor $\hat{\alpha}$ Axis Suppresses Cancer Stem Cell Properties. <i>Genes</i> , 2021, 12, 99.	2.4	24
27	Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine. <i>Anticancer Research</i> , 2016, 36, 6311-6318.	1.1	23
28	W9 peptide enhanced osteogenic differentiation of human adipose-derived stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 904-910.	2.1	22
29	A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel. <i>Anticancer Research</i> , 2018, 38, 4535-4542.	1.1	20
30	DGK $\hat{\eta}$ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. <i>Cellular Signalling</i> , 2012, 24, 1573-1582.	3.6	19
31	Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel. <i>Oncology Reports</i> , 2016, 35, 593-601.	2.6	19
32	AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes. <i>Anticancer Research</i> , 2018, 38, 5093-5099.	1.1	18
33	DGK $\hat{\eta}$ is involved in LPS-activated phagocytosis through IQGAP1/Rac1 pathway. <i>Biochemical and Biophysical Research Communications</i> , 2012, 420, 479-484.	2.1	17
34	Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis. <i>Journal of Biological Chemistry</i> , 2020, 295, 18328-18342.	3.4	17
35	Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo. <i>Oncotarget</i> , 2017, 8, 90996-91008.	1.8	17
36	Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells. <i>Anticancer Research</i> , 2014, 34, 4723-31.	1.1	17

#	ARTICLE	IF	CITATIONS
37	Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway. <i>Anticancer Research</i> , 2020, 40, 4961-4968.	1.1	16
38	<i>In vitro</i> and <i>in vivo</i> anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile. <i>Oncotarget</i> , 2019, 10, 3547-3558.	1.8	16
39	AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1. <i>Anticancer Research</i> , 2019, 39, 609-617.	1.1	16
40	AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel. <i>Anticancer Research</i> , 2018, 38, 6699-6706.	1.1	15
41	Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. <i>Anticancer Research</i> , 2019, 39, 4817-4828.	1.1	14
42	Spirolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. <i>Cancers</i> , 2019, 11, 1550.	3.7	13
43	Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing. <i>Biomedicines</i> , 2020, 8, 273.	3.2	13
44	Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11633.	4.1	13
45	Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. <i>Neuro-Oncology</i> , 2021, 23, 945-954.	1.2	11
46	Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction. <i>Life</i> , 2021, 11, 885.	2.4	11
47	Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab148.	0.7	7
48	Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. <i>Cancers</i> , 2022, 14, 1706.	3.7	5
49	Blood Supply-Susceptible Formation of Melanin Pigment in Hair Bulb Melanocytes of Mice. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2015, 3, e328.	0.6	3